Overview Financials News + Filings Key Docs Charts Ownership Insiders |
Tamir Biotechnology, Inc. (ACEL)
|
Add to portfolio |
|
|
Price: |
$13.25
| | Metrics |
OS: |
217.4
|
M
| |
|
|
Market cap: |
$2.88
|
B
| |
|
|
Net cash:
|
$782.6
|
k
| |
$0.00
|
per share
|
EV:
|
$2.88
|
B
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($115.9)
|
k
| |
|
|
EBIT
|
($123.2)
|
k
| |
|
|
EPS |
$0.00
| |
2721.6
|
x P/E
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Jul-31-12 | Jul-31-11 | Jul-31-10 | Jul-31-09 | Jul-31-08 | Jul-31-07 | Jul-31-06 | Jul-31-05 |
Revenues | 0.5 | 5.2 | 0.0 | 3.3 | 8.5 | 5.5 | 5.2 | 5.1 |
Revenue growth | -90.4% | 27633.3% | -99.4% | -61.6% | 53.4% | 6.0% | 2.9% | |
Cost of goods sold | 0.0 | 0.0 | 0.0 | 3.3 | 8.5 | 5.5 | 5.2 | 5.1 |
Gross profit | 0.5 | 5.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross margin | 100.0% | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Research and development | 0.3 | -0.9 | 0.5 | | | | | |
General and administrative | 0.3 | 0.2 | 1.7 | 2.4 | 5.8 | 4.1 | 3.0 | 1.8 |
EBIT | -0.1 | 4.6 | -2.2 | -5.7 | -14.3 | -9.6 | -8.2 | -6.9 |
EBIT margin | -11.9% | 88.2% | -11747.3% | -174.4% | -168.2% | -173.8% | -157.5% | -134.9% |
Pre-tax income | 2.0 | 14.1 | -14.2 | -4.5 | -12.3 | -8.8 | -7.8 | -6.5 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | 2.0 | 14.1 | -14.2 | -4.5 | -12.3 | -8.8 | -7.8 | -6.5 |
Net margin | 393.5% | 272.0% | -75663.8% | -138.9% | -144.9% | -157.9% | -149.3% | -127.1% |
|
Diluted EPS | $0.03 | $0.15 | ($0.30) | ($0.10) | ($0.26) | ($0.19) | ($0.21) | ($0.18) |
Shares outstanding (diluted) | 75.5 | 93.6 | 47.3 | 47.3 | 46.9 | 45.0 | 37.2 | 35.4 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|